Ex-Dividend Stocks: DuPont, AK Steel

NEW YORK ( TheStreet) -- The following stocks go ex-dividend Friday, meaning an investor must purchase the shares Thursday to qualify for the next dividend payment: DuPont ( DD), AK Steel ( AKS), Peabody Energy ( BTU), Exelon ( EXC), Herbalife ( HLF) and Eli Lilly ( LLY).

DuPont

The chemical company reported first-quarter earnings on April 19 of $1.49 billion, or $1.57 a share, up from year-earlier earnings of $1.43 billion, or $1.52.

"Meetings with DuPont's CEO reaffirmed our belief that the company's diverse and defensible portfolio (36% of earnings from recession-proof ag, nutrition and industrial biosciences) deserves to trade at premium to the S&P versus its current 8% discount (12.3x '12E EPS vs 13.4x)," Deutsche Bank analysts wrote in a report Tuesday.

Forward Annual Dividend Yield: 3.3%

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

AK Steel

The steel company reported on April 24 a first-quarter loss of $11.8 million, or 11 cents a share, a reversal from year-earlier earnings of $8.7 million, or 8 cents a share.

"We maintain an $8/shr price objective, using 9.4x 2012E and 8x '13E EV/EBITDA, compared with a historical forward 8.1x EV/EBITDA over the past 10 years, in line with more specialty metal peers, and 9.4x in the past three years," Bank of America Merrill Lynch analysts wrote in an April 25 report. "New electrical steel capacity globally has hurt margins, and we think vertical integration can have limited benefit ahead as carbon steel prices also slip with oversupply."

Forward Annual Dividend Yield: 2.9%


Peabody Energy

The coal mining company reported on April 19 first-quarter adjusted income from continuing operations of $191.2 million, or 64 cents a share, down from year-earlier earnings of $201 million, or 70 cents.

"We are maintaining our 2012 EPS estimate of $3.00 and 2013 EPS estimate of $4.25," Sterne Agee analysts wrote in an April 20 report. "Peabody Energy provides investors with the most attractive high-margin volume growth profile among global coal producers. We believe the market will be more focused on its value-creation strategy regarding McArthur and its ability to deliver growth out of Australia, where over 65% of future profits will be earned."

Forward Annual Dividend Yield: 1.2%

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Exelon

The utility company reported on May 4 first-quarter earnings of $200 million, or 28 cents a share, down from year-earlier earnings of $668 million, or $1.01 a share.

"We believe that EXC is attractive at current levels with an above average yield and upside leverage to improving US power markets," Jefferies analysts wrote in a report Monday.

Forward Annual Dividend Yield: 4%


Herbalife

The nutritional supplement company reported on April 30 first-quarter earnings of $108.2 million, or 88 cents a share, up from year-earlier earnings of $88.7 million, or 71 cents.

"In our view, the market is already starting to price in more than just a decelerated growth rate, but rather, potential that earnings power is below current consensus," Bank of America Merrill Lynch analysts wrote in a May 3 report. "We continue to believe that until a detailed investment thesis is revealed by Mr. Einhorn (assuming that is the path here), HLF is unlikely to find support in the market. In our view, an accelerated share buyback is just not enough to comfort concerned investors. We believe the business model meets legal and regulatory standards, suggesting to us that shares will rebound over time, but expect HLF to remain under pressure in the near-term."

Forward Annual Dividend Yield: 2.6%

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Eli Lilly

The pharmaceutical company reported on April 25 first-quarter earnings of $1.01 billion, or 91 cents a share, down from year-earlier earnings of $1.06 billion, or 95 cents.

"The shares continue to benefit from yield support and positive asymmetry around the solanezumab readout," Jefferies analysts wrote in a May 1 report. "Whilst a best case readout on solanezumab could lead to potential valuation upside of up to 60%, the more likely downside risk of 20-30% from failure leads us to reiterate our Hold rating."

Forward Annual Dividend Yield: 4.7%

-- Written by Alexandra Zendrian

>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to: tips@thestreet.com.

>To follow the writer on Twitter, go to Alexandra Zendrian.